We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

AI stocks are red-hot today. Last night Alphabet (Nasdaq: GOOGL) reported earnings and its stock is down 8% today. That ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

Nancy Pelosi's newest bet saw the purchase of Tempus AI call options — now, a Wall Street analyst has given the stock a new ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a ...